Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
voxtalisib
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Voxtalisib is an orally available, investigational small molecule that acts as a dual inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). It inhibits all class I PI3K isoforms (α, β, γ, δ) and both mTORC1 and mTORC2 complexes. By targeting these kinases in the PI3K/mTOR signaling pathway, voxtalisib disrupts cellular processes critical for cancer cell growth and survival. The drug was developed for the treatment of various cancers including lymphoma, glioblastoma, breast cancer, melanoma, chronic lymphocytic leukemia (CLL), mantle-cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), ovarian cancer, solid tumors and others. Clinical trials showed some efficacy in follicular lymphoma but limited activity in other aggressive lymphomas or CLL/SLL. Voxtalisib development has been discontinued for all indications[1][2][6][9].
- Other names
- voxtalisib
02
Targets
DNA-PK (DNA-dependent protein kinase)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CD (Phosphatidylinositol 3-kinase delta)Mechanistic target of rapamycin complex 1Mechanistic target of rapamycin kinase complex 2PIK3CA (Phosphoinositide 3-kinase alpha)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)
Beyond the preview
Go deeper on voxtalisib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on voxtalisib.